Logo image of BNTC

BENITEC BIOPHARMA INC (BNTC) Stock Fundamental Analysis

USA - NASDAQ:BNTC - US08205P2092 - Common Stock

15.81 USD
-0.02 (-0.13%)
Last: 10/23/2025, 4:30:02 PM
15.81 USD
0 (0%)
After Hours: 10/23/2025, 4:30:02 PM
Fundamental Rating

3

Taking everything into account, BNTC scores 3 out of 10 in our fundamental rating. BNTC was compared to 534 industry peers in the Biotechnology industry. While BNTC has a great health rating, there are worries on its profitability. BNTC is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

BNTC had negative earnings in the past year.
BNTC had a negative operating cash flow in the past year.
In the past 5 years BNTC always reported negative net income.
BNTC had a negative operating cash flow in each of the past 5 years.
BNTC Yearly Net Income VS EBIT VS OCF VS FCFBNTC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10M -20M -30M -40M

1.2 Ratios

BNTC's Return On Assets of -25.77% is fine compared to the rest of the industry. BNTC outperforms 72.28% of its industry peers.
The Return On Equity of BNTC (-27.78%) is better than 79.03% of its industry peers.
Industry RankSector Rank
ROA -25.77%
ROE -27.78%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BNTC Yearly ROA, ROE, ROICBNTC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K -6K -8K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BNTC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BNTC Yearly Profit, Operating, Gross MarginsBNTC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -5K -10K -15K -20K -25K

More info and screens

8

2. Health

2.1 Basic Checks

There is no outstanding debt for BNTC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BNTC Yearly Shares OutstandingBNTC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
BNTC Yearly Total Debt VS Total AssetsBNTC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

An Altman-Z score of 29.98 indicates that BNTC is not in any danger for bankruptcy at the moment.
BNTC has a Altman-Z score of 29.98. This is amongst the best in the industry. BNTC outperforms 93.63% of its industry peers.
There is no outstanding debt for BNTC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 29.98
ROIC/WACCN/A
WACCN/A
BNTC Yearly LT Debt VS Equity VS FCFBNTC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M

2.3 Liquidity

BNTC has a Current Ratio of 14.80. This indicates that BNTC is financially healthy and has no problem in meeting its short term obligations.
BNTC has a Current ratio of 14.80. This is amongst the best in the industry. BNTC outperforms 89.70% of its industry peers.
A Quick Ratio of 14.80 indicates that BNTC has no problem at all paying its short term obligations.
BNTC's Quick ratio of 14.80 is amongst the best of the industry. BNTC outperforms 89.70% of its industry peers.
Industry RankSector Rank
Current Ratio 14.8
Quick Ratio 14.8
BNTC Yearly Current Assets VS Current LiabilitesBNTC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 82.42% over the past year.
EPS 1Y (TTM)82.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -12.44% on average over the next years. This is quite bad
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-17.21%
EPS Next 2Y-12.44%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BNTC Yearly Revenue VS EstimatesBNTC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2028 10M 20M 30M
BNTC Yearly EPS VS EstimatesBNTC Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BNTC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BNTC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BNTC Price Earnings VS Forward Price EarningsBNTC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BNTC Per share dataBNTC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

BNTC's earnings are expected to decrease with -12.44% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-12.44%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

BNTC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BENITEC BIOPHARMA INC

NASDAQ:BNTC (10/23/2025, 4:30:02 PM)

After market: 15.81 0 (0%)

15.81

-0.02 (-0.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)09-22 2025-09-22/amc
Earnings (Next)11-12 2025-11-12
Inst Owners91.04%
Inst Owner Change0%
Ins Owners0.27%
Ins Owner Change0%
Market Cap415.01M
Revenue(TTM)N/A
Net Income(TTM)-27109000
Analysts87.14
Price Target26.69 (68.82%)
Short Float %5.14%
Short Ratio28.66
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)45.16%
Min EPS beat(2)32.35%
Max EPS beat(2)57.97%
EPS beat(4)3
Avg EPS beat(4)-15.07%
Min EPS beat(4)-165.05%
Max EPS beat(4)57.97%
EPS beat(8)4
Avg EPS beat(8)-143.3%
EPS beat(12)5
Avg EPS beat(12)-122.43%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.76%
PT rev (3m)1.76%
EPS NQ rev (1m)-7.41%
EPS NQ rev (3m)-7.41%
EPS NY rev (1m)-12.58%
EPS NY rev (3m)-15.82%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.25
P/tB 4.25
EV/EBITDA N/A
EPS(TTM)-1.47
EYN/A
EPS(NY)-1.72
Fwd EYN/A
FCF(TTM)-0.71
FCFYN/A
OCF(TTM)-0.71
OCFYN/A
SpS0
BVpS3.72
TBVpS3.72
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -25.77%
ROE -27.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.88%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.8
Quick Ratio 14.8
Altman-Z 29.98
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)82.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.18%
EPS Next Y-17.21%
EPS Next 2Y-12.44%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-40.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1.12%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y8.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y7.58%
OCF growth 3YN/A
OCF growth 5YN/A